Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.53 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169071 | 0.88 | PKN1 (0.67) | HCRTR1ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL11148656 | 0.86 | HCRTR1 (0.53) | HCRTR1ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL11824061 | 0.86 | SIRT2 (0.56) | HCRTR1ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL7795891 | 0.86 | HCRTR1 (0.53) | HCRTR1ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL5032566 | 0.85 | HSP90AA1 (0.53) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL14473811 | 0.85 | ALDH1A1 (0.53) | HCRTR1ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL12393006 | 0.85 | HRH3 (0.56) | HCRTR1ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL12393020 | 0.85 | ALDH1A1 (0.54) | HCRTR1ALDH1A1RAB9AKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL7324036 | 0.84 | HSP90AA1 (0.51) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL11249423 | 0.83 | HCRTR1 (0.51) | HCRTR1ALDH1A1RAB9AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810136-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-22 | — | — | US | disclosed |
| CN-112312908-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019243528-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2016-04-28 | — | — | US | disclosed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | HCRTR1 4347/4885ALDH1A1 487/4885RAB9A 3277/4885 |
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | LPO, NOTUM, FARS2 | HCRTR1 3282/4885ALDH1A1 1503/4885RAB9A 3735/4885 |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | HCRTR1 3392/4885ALDH1A1 3839/4885RAB9A 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.